Skip to content
Deka Biosciences, Inc logo — company profile

Deka Biosciences, Inc

Founded 2018 United States Germantown, United States 40 employees Venture round Total: $91.35M Biotechnology, Health Care

General Information

Company Name Deka Biosciences, Inc
Founded Year 2018
Location United States Germantown, United States
Employees 40
Industries Biotechnology, Health Care
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Deka Biosciences, Inc. To contact Deka Biosciences, Inc, visit dekabiosciences.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Deka Biosciences, Inc compare?

A PDF of Deka Biosciences, Inc and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Deka Biosciences, Inc soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Deka Biosciences, Inc

Deka Biosciences, Inc. is an early-stage biotechnology company founded in 2018 and headquartered in the United States. The company is focused on developing the next generation of targeted cytokine therapies to treat cancer and inflammatory diseases. Their innovative DiakineTM platform consists of optimized, stimulatory, or suppressive disease-specific IL-10 variants coupled to other stimulatory or suppressive cytokines using a T1/2 life-extending, tissue-targeting, non-immunogenic scFv technology. Deka Biosciences recently secured a significant $29.85M in funding on 08 December 2023, which marks a pivotal moment in their financial journey. The investors involved in this latest funding round are not disclosed, but this substantial investment underscores the confidence and potential seen in Deka Biosciences' innovative approach to biotechnology in the healthcare industry.

Business keywords: cancer therapy, inflammatory diseases, cytokine therapy, IL-10 variants, scFv technology, targeted therapies, biotech startup, immunotherapy, cancer treatment

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $29.85M -
08 Dec 2023
Series B $20.00M 10
MPM Capital, Viva BioInnovator +8
28 Sep 2023
Series B $21.50M -
01 Jan 2022
Series A $20.00M -
29 Oct 2021

Deka Biosciences, Inc Alternatives & Competitors

View All Alternatives
Deka Biosciences, Inc vs

Engineering the future of targeted medicines, breaking barriers to develop the next generation thera...

Post-IPO Equity
15 employees
Biotechnology, Health Care
Deka Biosciences, Inc vs
NEOVACS
NEOVACS France

Nous développons les thérapies de demain et investissons dans des sociétés innovantes en Biotech et...

Post-IPO Equity
18 employees
Biotechnology, Health Care
Deka Biosciences, Inc vs
Orum Therapeutics
Orum Therapeutics United States

A public biotechnology company pioneering a novel class of protein degraders.

IPO
55 employees
Biotechnology, Health Care

FAQ About Deka Biosciences, Inc

Deka Biosciences, Inc., is an early-stage biotechnology company focused on generating the next generation targeted cytokine therapies to treat cancer and inflammatory diseases. Deka is developing the dual cytokine, (DiakineTM) platform. Diakines are comprised of optimized, stimulatory, or suppressiv...
Deka Biosciences, Inc was founded in 2018.
Deka Biosciences, Inc is headquartered in Germantown, United States.
Deka Biosciences, Inc operates in Biotechnology and Health Care. Its work centres on cancer therapy, inflammatory diseases, cytokine therapy and IL-10 variants.
Deka Biosciences, Inc has approximately 40 employees.
Deka Biosciences, Inc has completed 4 funding rounds, raising a total of $91.35M. The latest funding stage is Venture round.
Top alternatives and competitors to Deka Biosciences, Inc include VBL Therapeutics (Nasdaq:VBLT), NEOVACS, Orum Therapeutics, Prescient Therapeutics, iOnctura. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Deka Biosciences, Inc and VBL Therapeutics (Nasdaq:VBLT) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Deka Biosciences, Inc, https://bouncewatch.com/company/deka-biosciences-inc, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout